Daily Bulletin

Men's Weekly

.

Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

- First approved allogeneic cell therapy product globally for the treatment of CLI

- Developed by Stempeutics over a period of twelve years, breakthrough treatment designed to address root cause of the disease at an affordable cost

- Cipla to market and distribute the drug in India to provide patient access

Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)

MUMBAI, India, Aug. 21, 2020 /PRNewswire/...

Read more: Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to...

Business News

Why Small Business is the Latest Casualty of the Cost-of-Living Crisis

The Australian small to medium enterprise (SME) sector is currently navigating a systemic crisis defined by the convergence of high operational costs and severely constrained consumer demand. This env...

Daily Bulletin - avatar Daily Bulletin

Telematics Boosts Australian Business Efficiency

Telematics—the clever fusion of telecommunications and information technology—is rapidly becoming the cornerstone of smarter operations for businesses across Australia. Faced with the unique challen...

Daily Bulletin - avatar Daily Bulletin

Choosing Local Stainless Steel Fabrication and Laser Cutting in Brisbane

Stainless steel is one of the most widely used materials in industries today due to its strength, durability, and resistance to corrosion and rust. For architectural elements, industrial equipment, ...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business